JNJ

171.3

+0.78%↑

AZN

73.93

-0.54%↓

NVS

114.18

-3.11%↓

ABT

131.21

+1.02%↑

UNH

246.86

+2.58%↑

JNJ

171.3

+0.78%↑

AZN

73.93

-0.54%↓

NVS

114.18

-3.11%↓

ABT

131.21

+1.02%↑

UNH

246.86

+2.58%↑

JNJ

171.3

+0.78%↑

AZN

73.93

-0.54%↓

NVS

114.18

-3.11%↓

ABT

131.21

+1.02%↑

UNH

246.86

+2.58%↑

JNJ

171.3

+0.78%↑

AZN

73.93

-0.54%↓

NVS

114.18

-3.11%↓

ABT

131.21

+1.02%↑

UNH

246.86

+2.58%↑

JNJ

171.3

+0.78%↑

AZN

73.93

-0.54%↓

NVS

114.18

-3.11%↓

ABT

131.21

+1.02%↑

UNH

246.86

+2.58%↑

Search

AbbVie Inc

Aperta

SettoreSettore sanitario

195.64 -1.43

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

194.59

Massimo

198.68

Metriche Chiave

By Trading Economics

Entrata

1.3B

1.3B

Vendite

2.1B

15B

P/E

Media del settore

92.578

34.393

EPS

2.97

Rendimento da dividendi

3.31

Margine di Profitto

9.66

Dipendenti

55,000

EBITDA

-4.3B

117M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+9.14% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.31%

2.54%

Utili prossimi

29 ott 2025

Prossima data del Dividendo

15 ago 2025

Prossima data del' Ex Dividendo

14 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

12B

348B

Apertura precedente

197.07

Chiusura precedente

195.64

Notizie sul Sentiment di mercato

By Acuity

14%

86%

18 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

AbbVie Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 lug 2025, 12:46 UTC

Utili

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30 giu 2025, 13:02 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25 apr 2025, 13:57 UTC

Utili

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 apr 2025, 12:52 UTC

Utili

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

31 lug 2025, 12:08 UTC

Utili

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31 lug 2025, 11:46 UTC

Utili

AbbVie Raises FY Outlook

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q Adj EPS $2.97 >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q EPS 52c >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q Rev $15.42B >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31 lug 2025, 11:44 UTC

Utili

AbbVie 2Q Net $938M >ABBV

30 giu 2025, 12:47 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 giu 2025, 12:33 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 giu 2025, 12:33 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 giu 2025, 12:32 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 giu 2025, 12:31 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 mag 2025, 09:30 UTC

Notizie principali

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 apr 2025, 12:44 UTC

Utili

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 apr 2025, 09:33 UTC

Utili

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 apr 2025, 16:03 UTC

Utili

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 apr 2025, 14:00 UTC

Notizie principali
Utili

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr 2025, 12:24 UTC

Notizie principali
Utili

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr 2025, 12:03 UTC

Notizie principali
Utili

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Confronto tra pari

Modifica del prezzo

AbbVie Inc Previsione

Obiettivo di Prezzo

By TipRanks

9.14% in crescita

Previsioni per 12 mesi

Media 215.21 USD  9.14%

Alto 255 USD

Basso 170 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AbbVie Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

16 ratings

10

Acquista

6

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

180.37 / 195.54Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

18 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.